Personalized testing to check drug interactions and gene effects
Part of Cancer, Mental health clinical trials.
This study uses personalized information to help understand how your current medicines interact with each other and with your genes. It may help your care team choose safer, more effective medication plans for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (age 18 or older).
- You currently receive care from a University of Chicago Medical Center provider who is part of this clinic.
- You take at least 5 medications and you’re on a “perpetrator” medicine (one that can change how other drugs work) or a medicine where gene information can guide choices.
- You have not had a liver or kidney transplant planned or started being considered.
- You are not in another pharmacogenomics (gene-guided medicine) study and you haven’t had genetic testing elsewhere.
- You can understand the study and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood, urine, and cheek swabs, along with health information, to see how your genes affect your response to medications. You may be eligible if you take many medications or are on blood pressure or depression medication.
This trial studies how doing genetic (DNA) testing on your cancer helps doctors choose targeted treatments, and how those treatments affect outcomes. It is for adults whose cancer has not responded to the first standard treatment or who do not have curative options.
This trial is testing whether a new system that connects genetic test results to your medical records can help reduce healthcare gaps for people with advanced cancer. It may help your doctor better personalize your treatment.
This Phase 2 study uses a team review of your tumor’s gene test results to help match you with treatments you may benefit from. It’s designed for people whose tumor has specific gene changes that suggest sensitivity to available medicines or may involve inherited (germline) risk.
This study looks at how to put genetic testing results (pharmacogenomics) into regular doctor care. It aims to see whether using the results helps doctors choose safer, better-matched medications.
This trial tests whether a “point-of-care” computer tool can help clinicians use a person’s genetic information to choose safer, better medication decisions. It focuses on helping reduce treatment differences for African American patients.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.